NNVC vs. IMUX, COYA, CLRB, ALLK, DMAC, PDSB, CYTT, CLSD, VTGN, and TLSA
Should you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Immunic (IMUX), Coya Therapeutics (COYA), Cellectar Biosciences (CLRB), Allakos (ALLK), DiaMedica Therapeutics (DMAC), PDS Biotechnology (PDSB), Cyteir Therapeutics (CYTT), Clearside Biomedical (CLSD), Vistagen Therapeutics (VTGN), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical preparations" industry.
NanoViricides (NYSE:NNVC) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.
10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 4.6% of NanoViricides shares are owned by company insiders. Comparatively, 3.0% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
NanoViricides has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.
Immunic has a consensus target price of $8.50, suggesting a potential upside of 585.48%. Given Immunic's higher probable upside, analysts clearly believe Immunic is more favorable than NanoViricides.
In the previous week, NanoViricides and NanoViricides both had 2 articles in the media. Immunic's average media sentiment score of 0.29 beat NanoViricides' score of -0.01 indicating that Immunic is being referred to more favorably in the news media.
NanoViricides' return on equity of -74.66% beat Immunic's return on equity.
NanoViricides is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
Immunic received 94 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 65.73% of users gave Immunic an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
Summary
Immunic beats NanoViricides on 8 of the 13 factors compared between the two stocks.
Get NanoViricides News Delivered to You Automatically
Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NanoViricides Competitors List
Related Companies and Tools
